Test intended for patients 40-80 years of age. Stratifies risk of aggressive prostate cancer in patients with elevated PSA for whom biopsy is being considered. Test should not be ordered if (1) prostate cancer was previously diagnosed; (2) digital rectal exam was performed within the last 4 days; (3) any procedure or therapy was used to treat symptomatic benign prostatic hyperplasia (BPH) within the past 6 months; (4) any invasive, urologic procedure that may be associated with a secondary PSA evaluation was done within the past 6 months; (5) 5-alpha reductase inhibitor (5-ARI) therapy, such as Avodart (dutasteride) or Proscar (finasteride), was administered within the past 6 months.
- Patient Preparation
- Serum Separator Tube (SST).
- Specimen Preparation
- Transfer 4 mL serum to an ARUP Standard Transport Tube. (Min: 3 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- Biopsy history must be provided.
- Ambient: Unacceptable; Refrigerated: 72 hours; Frozen: 2 months
|Component Test Code*||Component Chart Name||LOINC|
|2014060||4K - Biopsy History|
|2014061||4K - Digital Rectal Exam (DRE)|
|2014063||4K - Score|
|2014309||4K - PSA, Total|
|2014310||4K - PSA, Free|
|2014311||4K - PSA, Percent Free|
|3000586||4K - Order Discussed with Patient|
|3000587||4K - Patient History|
- 4K Prostate Screen; Prostate test
- Kallikrein score
Performed at BioReference Laboratories